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background:  Recently a considerable number of patients have Non-vitamin K antagonist oral anticoagulant (NOAC) for Atrial fibrillation 
(AF). Some AF patients have NOAC concurrent antiplatelet therapy for atherosclerosis. However there are few reports about bleeding 
events among NOAC patients with concurrent antiplatelet therapy in real world.
Methods: We examined a consecutive retrospective anticoagulant database April 2011 till August 2014 at a single tertiary referral center. A 
consecutive cohort of 1585 patients (1025 were men, mean age was 70±11 years, mean BMI was 23.5, Paroxysmal AF 65%, Persistent AF 
13.8%, Long standing persistent AF 21%, mean creatinine clearance was 76.6ml/min, mean CHADS score was 1.7 point, mean HASBLED 
score was 1.1 point, Dabigatran N=1122, Ribaroxaban N=266, Apixaban N=197) was studied. Clinical characteristics, bleeding events and 
outcomes were analyzed. We categorized bleeding events by Bleeding Academic Research Consortium (BARC) definition and consider 
above type 3 bleeding events as clinically severe.
results: All BARC types of bleeding event rate were 6.42% (72/1122) in Dabigatran, 5.64% (15/266) in Ribaroxaban, and 3.55% (7/197) 
in Apixaban respectively. There was a significant difference between Dabigatran monotherapy and Dabigatran with antiplatelet therapy 
(5.79% (55/950) vs 9.88% (17/172): p=0.04), while not in the other NOAC (Rivaroxaban: 5.76% (14/243) vs 4.35% (1/23), Apixaban: 3.43% 
(6/175) vs 4.55% (1/22)). However there was no difference between all NOAC and NOAC with antiplatelet therapy in severe bleeding 
events (p=0.41, p=0.66, p=0.21).
Conclusion:  Dabigatran with antiplatelet therapy increases the bleeding events compared to Dabigatran monotherapy. However no 
difference was seen in all NOAC about severe bleeding events.
